2023
Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
Fitzpatrick M, Moghadas S, Vilches T, Shah A, Pandey A, Galvani A. Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination. JAMA Network Open 2023, 6: e2313586. PMID: 37204795, PMCID: PMC10199352, DOI: 10.1001/jamanetworkopen.2023.13586.Peer-Reviewed Original ResearchConceptsBooster campaignBooster vaccinationInfluenza vaccinationPediatric populationDecision analytical modelSchool absenteeismIntensive carePediatric hospitalizationsEligible individualsMAIN OUTCOMEAge groupsIntensive care unit admissionCare unit admissionSeasonal influenza vaccinationCOVID-19 illnessCOVID-19 prevention strategiesEligible age groupDecreased hospitalizationsUnit admissionCOVID-19 transmissionSymptomatic infectionAdverse outcomesIsolation daysHospitalizationGeneral population
2022
Return on Investment of the COVID-19 Vaccination Campaign in New York City
Sah P, Vilches T, Moghadas S, Pandey A, Gondi S, Schneider E, Singer J, Chokshi D, Galvani A. Return on Investment of the COVID-19 Vaccination Campaign in New York City. JAMA Network Open 2022, 5: e2243127. PMID: 36409495, PMCID: PMC9679875, DOI: 10.1001/jamanetworkopen.2022.43127.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccination campaignVaccination campaignIntensive care unit admissionCare unit admissionEmergency department visitsIndirect costsDecision analytical modelEmergency medical servicesCOVID-19 deathsHealth care expendituresUnit admissionDepartment visitsFuture COVID-19 outbreaksNew York CityOutpatient visitsVaccine uptakeSevere outcomesVaccination programPotential yearsMAIN OUTCOMEVaccinationHealth outcomesProbable casesSocietal perspectiveCare expenditures
2021
Estimated Prevalence of Smoking and Smoking-Attributable Mortality Associated With Graphic Health Warnings on Cigarette Packages in the US From 2022 to 2100
Tam J, Jeon J, Thrasher JF, Hammond D, Holford TR, Levy DT, Meza R. Estimated Prevalence of Smoking and Smoking-Attributable Mortality Associated With Graphic Health Warnings on Cigarette Packages in the US From 2022 to 2100. JAMA Health Forum 2021, 2: e212852. PMID: 35977179, PMCID: PMC8796938, DOI: 10.1001/jamahealthforum.2021.2852.Peer-Reviewed Original ResearchConceptsSmoking-attributable deathsGraphic health warningsSmoking-attributable mortalityDecision analytical modelHealth warningsCigarette packagesPrevalence of smokingAdult smoking prevalenceSurveillance Modeling NetworkPopulation health outcomesPublic health benefitsPrimary outcomeSmoking prevalenceMAIN OUTCOMEUS FoodDrug AdministrationHealth outcomesMore deathsCancer interventionSmokingHealth harmsHealth benefitsPrevalenceDeathOutcomesSeizure Prophylaxis After Spontaneous Intracerebral Hemorrhage
Jones F, Sanches P, Smith J, Zafar S, Blacker D, Hsu J, Schwamm L, Newhouse J, Westover M, Moura L. Seizure Prophylaxis After Spontaneous Intracerebral Hemorrhage. JAMA Neurology 2021, 78: 1128-1136. PMID: 34309642, PMCID: PMC8314179, DOI: 10.1001/jamaneurol.2021.2249.Peer-Reviewed Original ResearchConceptsEarly seizure prophylaxisSpontaneous intracerebral hemorrhageAdverse drug reactionsRisk-guided strategyLate seizuresLong-term therapyHigh riskSeizure prophylaxisPrimary prophylaxisIntracerebral hemorrhageLower riskLong-term adverse drug reactionsLow-risk patientsShort-term prophylaxisDecision analytical modelSecondary therapyProphylaxis strategiesDrug reactionsProphylaxisMAIN OUTCOMESeizuresPatientsClinical decisionTherapyAverage riskProjected Estimates of Opioid Mortality After Community-Level Interventions
Linas BP, Savinkina A, Madushani RWMA, Wang J, Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Network Open 2021, 4: e2037259. PMID: 33587136, PMCID: PMC7885041, DOI: 10.1001/jamanetworkopen.2020.37259.Peer-Reviewed Original ResearchConceptsCommunity-level interventionsOverdose mortalityOpioid overdoseUse of MOUDDistribution of naloxoneOpioid overdose deathsDecision analytical modelOpioid overdose ratesMOUD retentionOUD populationOpioid mortalityMAIN OUTCOMEMOUDNaloxone distributionOverdose deathsOverdose ratesSingle interventionMortalityNaloxoneInterventionMonthsOverdoseProjected estimatesHuman ServicesOutcomes
2018
The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2016
Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases
Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases. Hepatology 2016, 64: 1331-1342. PMID: 26926906, DOI: 10.1002/hep.28527.Peer-Reviewed Original ResearchConceptsHealth economic evaluationsEconomic evaluationAlternative health care interventionsDecision analytical modelingCost-effectiveness analysisHealth economic analysisDecision analytical modelDecision analytic modelHealth care interventionsEconomic analysisEconomic sustainabilityHealth care costsBudget impactDecision makersMedical innovationCare costsSocioeconomic contextSustainabilityCare interventionsFair accessMarketMakersAnalytical toolsInnovationCurrent context
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply